Last reviewed · How we verify
Estradiol valerate 2 mg, cyproterone acetate 25 mg
Estradiol valerate 2 mg, cyproterone acetate 25 mg is a Small molecule drug developed by Thai Red Cross AIDS Research Centre. It is currently in Phase 1 development.
At a glance
| Generic name | Estradiol valerate 2 mg, cyproterone acetate 25 mg |
|---|---|
| Sponsor | Thai Red Cross AIDS Research Centre |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women (NA)
- Drug-Drug Interaction Study in Trans Women Living With HIV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol valerate 2 mg, cyproterone acetate 25 mg CI brief — competitive landscape report
- Estradiol valerate 2 mg, cyproterone acetate 25 mg updates RSS · CI watch RSS
- Thai Red Cross AIDS Research Centre portfolio CI
Frequently asked questions about Estradiol valerate 2 mg, cyproterone acetate 25 mg
What is Estradiol valerate 2 mg, cyproterone acetate 25 mg?
Estradiol valerate 2 mg, cyproterone acetate 25 mg is a Small molecule drug developed by Thai Red Cross AIDS Research Centre.
Who makes Estradiol valerate 2 mg, cyproterone acetate 25 mg?
Estradiol valerate 2 mg, cyproterone acetate 25 mg is developed by Thai Red Cross AIDS Research Centre (see full Thai Red Cross AIDS Research Centre pipeline at /company/thai-red-cross-aids-research-centre).
What development phase is Estradiol valerate 2 mg, cyproterone acetate 25 mg in?
Estradiol valerate 2 mg, cyproterone acetate 25 mg is in Phase 1.